The shadow of generic challenges has long loomed over copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the outlook of similar drug ventures. While initial years saw impressive profits, the intellectual property lapse has allowed the door for discounted substitutes, likely diminishing revenue and presenting a genuine risk for